{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-035735","form_type":"8-K","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.393651+00:00","generated_at":"2026-05-23T05:14:15.388635+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager","bullets":["ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.","Up to 2-fold increase in tumor suppression vs. runimotamab biosimilar in HER2-overexpressing cancer models.","Reduced cytokine release and tolerated >180x the MTD of parental antibody in monkeys, suggesting wider therapeutic window.","Phase 1 clinical trials planned to commence in first half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-035735","json":"https://secwatch.observer/filing/0001213900-25-035735.json","markdown":"https://secwatch.observer/filing/0001213900-25-035735.md","text":"https://secwatch.observer/filing/0001213900-25-035735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/0001213900-25-035735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/ea0239349-8k_abprohold.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:14:15.388635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}